Suscribirse

Age and vitamin D affect the magnitude of the antibody response to the first dose of the SARS-CoV-2 BNT162b2 vaccine - 07/05/22

Doi : 10.1016/j.retram.2022.103344 
Isabelle Piec a, Laura Cook b, Samir Dervisevic a, c, William D Fraser a, b, Scott Ruetten d, Marvin Berman d, Emma English a, b, , W Garry John a, b,
a Faculty of Medicine and Health, University of East Anglia, Norwich, UK 
b Department of Clinical Biochemistry, Norfolk and Norwich University Hospitals Trust, Norwich, UK 
c Virology Department, Norfolk and Norwich University Hospitals Trust, Norwich, UK 
d Abbott Diagnostics, 100 Abbott Park, Abbott Park, IL 60046, United States 

Corresponding authors.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Highlights

Evidence before this study Immunization is the most important strategy to facilitate the end of the global pandemic. Vaccines, authorized for use globally, have shown more than 90% efficacy against SARS-CoV-2 clinical disease in clinical trials. In an effort to ensure maximal coverage by vaccinating as many people as possible with one dose (of the 2-dose vaccines such as the Pfizer/BioNTech) the UK government extended the recommended interval for the second dose from three to twelve weeks. To date, most studies only evaluate the serological response at a single time point post 1st dose or investigate the antibody response up to three weeks. Many studies simply look for the qualitative absence or presence of antibodies with a very limited number investigating the quantitative antibody response over an extended time period. In addition, most studies do not investigate factors which affect the magnitude of antibody response.
Added value of this study This is the first study to quantify antibody concentrations at multiple time points post first dose of the BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in Healthcare workers, with no known previous infection, showing positive concentrations of IgG after 8 weeks. Moreover, younger deciles (≤40yr) showed an initial greater antibody production. Levels at week 8 were similar across ages. Vitamin D concentrations ≥50nmol/L improved the antibody response to a dose of SARS-CoV-2 BNT162b2 (Pfizer/BioNTech) vaccine.
Implications of all the available evidence Both younger and older adults retained positive concentrations of antibodies against SARS-CoV-2, 8 weeks after the first dose of vaccine. Booster immunization should be administered following sunshine exposure or after vitamin D supplementation.

El texto completo de este artículo está disponible en PDF.

Abstract

Background

Most approved vaccines utilise a two-dose strategy. To enable larger groups of patients to receive the first dose, the UK government increased the gap between the two doses from three to twelve weeks. Here we report on the immunogenicity of the first dose, including effect of age and vitamin D status on these levels over an 8 week-period.

Methods

Blood samples were collected from healthcare workers (HCW) receiving their first BNT162b2 vaccine dose between January and February 2021. Antibody (Ab) production was measured, prior to and weekly for 4 weeks post immunization, and a final measurement was performed at 8 weeks. Serum vitamin D concentrations were also measured at baseline.

Findings

Immunization of 97 HCW induced an Ab response that peaked 3•2 weeks post immunization to decrease thereafter. Ab levels remained positive at 8 weeks. IgG peak concentration was negatively associated with age (β=-0•440, p<0.001). Response to immunization was also significantly affected by vitamin D status (p=0•022), on average 29•3% greater peak value in individuals with 25(OH)D>50nmol/L. No other variable showed significant effect.

Interpretation

The first dose of BNT162b2 produced Ab levels that remained positive after 8 weeks. Peak was greater in younger subjects and 25(OH)D>50nmol/L was beneficial. Booster campaigns should take into consideration vitamin D status which is at its highest following a period of sunshine exposure or following oral supplementation (400-1000IU daily).

Funding

Abbott Diagnostics Ltd supplied the kits used to quantify the anti-SARS -CoV-2 Spike IgG and technical support as well as provided financial support for sample collections.

El texto completo de este artículo está disponible en PDF.

Keywords : SARS-CoV-2, immunization, BNT162b2, Vitamin D, Age


Esquema


© 2022  Publicado por Elsevier Masson SAS.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 70 - N° 3

Artículo 103344- juillet 2022 Regresar al número
Artículo precedente Artículo precedente
  • Fetal hemoglobin modulates neurocognitive performance in sickle cell anemia✰,✰✰
  • Andrew M. Heitzer, Jennifer Longoria, Evadnie Rampersaud, Sara R. Rashkin, Jeremie H. Estepp, Victoria I. Okhomina, Winfred C. Wang, Darcy Raches, Brian Potter, Martin H. Steinberg, Allison A. King, Guolian Kang, Jane S. Hankins

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.